He coined the term “entactogen” (later sometimes called “empathogen”) in the mid-1980s to describe the distinct pharmacological class of MDMA-like substances that produce emotional openness and empathy rather than classical hallucinations.

 Explore David Nichols' research

David E. Nichols (born 1944) is an American medicinal chemist and pharmacologist widely regarded as one of the world’s leading experts on the chemistry and pharmacology of psychedelic and related compounds. He spent most of his career at Purdue University (Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology) and is a co-founder and long-time leader of the Heffter Research Institute.Main research focusNichols has worked for more than five decades on the structure–activity relationships (SAR) of compounds that act on the central nervous system, with particular emphasis on:

• Classical psychedelics (LSD and other lysergamides, psilocybin/psilocin, DMT, mescaline and its analogues)
• The serotonin 5-HT₂A receptor (the primary target of classical psychedelics)
• MDMA and related compounds
• Dopamine receptor ligands (including work relevant to Parkinson’s disease)

He coined the term “entactogen” (later sometimes called “empathogen”) in the mid-1980s to describe the distinct pharmacological class of MDMA-like substances that produce emotional openness and empathy rather than classical hallucinations.Work relevant to 4-MTAIn the early 1990s, while investigating selective serotonin-releasing agents as potential research tools or antidepressant leads, Nichols’ laboratory synthesized and studied 4-methylthioamphetamine (4-MTA, also called p-methylthioamphetamine or MTA).Key findings from their animal (primarily rat) studies, published between 1992 and 1997:

• 4-MTA is a potent and relatively selective serotonin releaser.
• It is also a reversible inhibitor of monoamine oxidase A (MAO-A).
• In drug-discrimination tests, rats responded to 4-MTA in a manner similar to MDMA.
• Unlike some related compounds (e.g., PCA), it appeared to lack long-term serotonin neurotoxicity in the animal models used at the time.
• The combination of strong serotonin release + MAO-A inhibition was noted as a potential source of risk (serotonin syndrome).

Nichols has repeatedly stated that the work was intended purely for laboratory research into the serotonin transporter and possible therapeutic applications (e.g., as a more selective alternative to existing antidepressants). He has expressed deep regret that the published data were later used by others to produce the recreational drug sold as “Flatliners,” which was linked to several deaths in Europe in the late 1990s. In a 2011 Nature commentary he wrote that he was “haunted” by the unintended consequences.Broader contributions

• Synthesized research quantities of MDMA, psilocybin, and DMT used in key human studies (including early MAPS MDMA trials and Rick Strassman’s DMT work).
• Extensive mapping of how small chemical changes alter receptor binding and behavioural effects.
• Foundational reviews on hallucinogens and serotonin receptors that remain highly cited.
• Advocacy for rigorous, controlled scientific study of psychedelics through the Heffter Research Institute (founded 1993), which helped restart modern clinical research after decades of restriction.

Nichols’ career is characterized by meticulous medicinal chemistry aimed at understanding how molecular structure determines biological activity in the brain. While some of his published compounds later appeared on the illicit market, his stated goal throughout has been therapeutic and scientific insight rather than recreational use.